Literature DB >> 25024626

Expression of P450 and nuclear receptors in normal and end-stage Chinese livers.

Hong Chen1, Zhong-Yang Shen1, Wang Xu1, Tie-Yan Fan1, Jun Li1, Yuan-Fu Lu1, Ming-Liang Cheng1, Jie Liu1.   

Abstract

AIM: To investigate the expression of P450 enzyme genes by using end-stage liver disease samples and trimmed normal Chinese donor livers.
METHODS: The end-stage liver disease samples [n = 93, including hepatocellular carcinoma (HCC), peri-HCC tissue, hepatitis B virus cirrhosis, alcoholic cirrhosis, and severe cirrhosis] and trimmed normal Chinese donor livers (n = 35) from The Institute of Organ Transplantation in Beijing, China. Total RNA was extracted, purified, and subjected to real-time RT-PCR analysis.
RESULTS: For cytochrome P450 enzymes 1 (CYP1) family, the expression of CYP1A2 was decreased 90% in HCC, 80% in alcoholic cirrhosis, and 65% in severe cirrhosis. For CYP2 family, the expression of CAR was decreased 50% in HCC, but increased 50% in peri-HCC tissues. Similar decreases (about 50%) of CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 were observed in HCC, as compared to peri-HCC tissues and normal livers. CYP2C19 were decreased in all end-stage liver diseases and CYP2E1 also decreased in alcoholic cirrhosis and severe cirrhosis. For CYP3 family, the expression of PXR was decreased 60% in HCC, together with decreases in CYP3A4, CYP3A5, and CYP3A7. In contrast, the expression of CYP3A7 was slightly increased in HBV cirrhosis. The expression of CYP4A11 was decreased 85% in HCC, 7% in alcoholic cirrhosis and severe liver cirrhosis, along with decreases in PPARα. The 93 end-stage livers had much higher inter-individual variations in gene expression than 35 normal livers.
CONCLUSION: The expression of CYP enzyme genes and corresponding nuclear receptors was generally decreased in end-stage liver diseases, and significant differences in gene expression were evident between peri-HCC and HCC.

Entities:  

Keywords:  Chinese donor livers; Cytochrome P450; End-stage livers; Hepatocellular carcinoma; Nuclear receptors; mRNA expression

Mesh:

Substances:

Year:  2014        PMID: 25024626      PMCID: PMC4093721          DOI: 10.3748/wjg.v20.i26.8681

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

Authors:  Kazuhiko Hanada; Kenya Nakai; Hiromasa Tanaka; Fumitaka Suzuki; Hiromitsu Kumada; Yasuo Ohno; Shogo Ozawa; Hiroyasu Ogata
Journal:  Drug Metab Pharmacokinet       Date:  2011-12-13       Impact factor: 3.614

2.  MRNA levels of two different enzymes in hepatocellular carcinoma.

Authors:  Yao-Xian Wang; Xiang-Wei Meng; Yin-Dong Wang; Ying Liu
Journal:  Hepatogastroenterology       Date:  2010 Sep-Oct

3.  Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease.

Authors:  Mika J Jokinen; Pertti J Neuvonen; Leena Lindgren; Krister Höckerstedt; Jan Sjövall; Olof Breuer; Yvonne Askemark; Jouni Ahonen; Klaus T Olkkola
Journal:  Anesthesiology       Date:  2007-01       Impact factor: 7.892

Review 4.  Pharmacogenetic biomarkers: cytochrome P450 3A5.

Authors:  Iain A M MacPhee
Journal:  Clin Chim Acta       Date:  2011-10-18       Impact factor: 3.786

Review 5.  Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.

Authors:  J Aubert; K Begriche; L Knockaert; M A Robin; B Fromenty
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-06-12       Impact factor: 2.947

6.  Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver.

Authors:  Susanne Haas; Sabine Merkelbach-Bruse; Christina Justenhoven; Hiltrud Brauch; Hans-Peter Fischer
Journal:  Pathol Res Pract       Date:  2009-07-10       Impact factor: 3.250

Review 7.  The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

Authors:  Reem H Elbekai; Hesham M Korashy; Ayman O S El-Kadi
Journal:  Curr Drug Metab       Date:  2004-04       Impact factor: 3.731

8.  CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.

Authors:  Albader Albarmawi; David Czock; Annika Gauss; Robert Ehehalt; Justo Lorenzo Bermejo; Jürgen Burhenne; Tom M Ganten; Peter Sauer; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

9.  Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1.

Authors:  Mateusz Kurzawski; Violetta Dziedziejko; Mariola Post; Maciej Wójcicki; Elżbieta Urasińska; Janusz Miętkiewski; Marek Droździk
Journal:  Pharmacol Rep       Date:  2012       Impact factor: 3.024

Review 10.  Cytochrome p450 and chemical toxicology.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2007-12-06       Impact factor: 3.739

View more
  23 in total

Review 1.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients.

Authors:  Tongmeng Yan; Linlin Lu; Cong Xie; Jiamei Chen; Xiaojuan Peng; Lijun Zhu; Ying Wang; Qiang Li; Jian Shi; Fuyuan Zhou; Ming Hu; Zhongqiu Liu
Journal:  Mol Cancer Ther       Date:  2015-10-29       Impact factor: 6.261

Review 3.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

4.  Role of miR-653 and miR-29c in downregulation of CYP1A2 expression in hepatocellular carcinoma.

Authors:  Martin Krkoška; Jana Nekvindová; Kateřina Nevědělová; Veronika Zubáňová; Lenka Radová; Jan Vondráček; Jarmila Herůdková; Ondřej Slabý; Igor Kiss; Lucia Bohovicová; Pavel Fabian; Zuzana Tylichová; Zdeněk Kala; Petr Kysela; Lenka Ostřížková; Vladimír Palička; Alena Hyršlová Vaculová
Journal:  Pharmacol Rep       Date:  2021-11-15       Impact factor: 3.024

5.  Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway.

Authors:  J Xue; W Zhu; J Song; Y Jiao; J Luo; C Yu; J Zhou; J Wu; M Chen; W-Q Ding; J Cao; S Zhang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

6.  Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.

Authors:  Jianqing Yu; Nuozhou Wang; Zhongqin Gong; Liping Liu; Shengli Yang; George Gong Chen; Paul Bo San Lai
Journal:  Oncogene       Date:  2020-11-12       Impact factor: 9.867

7.  Diffusion of information throughout the host interactome reveals gene expression variations in network proximity to target proteins of hepatitis C virus.

Authors:  Ettore Mosca; Roberta Alfieri; Luciano Milanesi
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

8.  Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma.

Authors:  D Fanni; M Manchia; F Lai; C Gerosa; R Ambu; G Faa
Journal:  Eur J Histochem       Date:  2016-04-11       Impact factor: 3.188

9.  Hepatic Deficiency of Augmenter of Liver Regeneration Exacerbates Alcohol-Induced Liver Injury and Promotes Fibrosis in Mice.

Authors:  Sudhir Kumar; Jiang Wang; Richa Rani; Chandrashekhar R Gandhi
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

10.  Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.

Authors:  Jianwai Ren; George G Chen; Yi Liu; Xianwei Su; Baoguang Hu; Billy C S Leung; Y Wang; Rocky L K Ho; Shengli Yang; Gang Lu; C G Lee; Paul B S Lai
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.